Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
0
Authors
Jerald Sadoff
Jerald Sadoff•Glenda Gray•Macaya Douoguih
Published
February 9, 2022
Abstract
The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis.
